الفهرس 
Liver cirrhosisOnly 14 pages are availabe for public view
 |  | from | 106 |  |  |
| | | from | 106 | | |
Abstract
Liver functions include the synthesis of vitamin K dependent clotting factors. Thus, an impaired liver function leads to an increased bleeding tendency caused by a deficiency of those factors and of thrombocytes. On the other hand, liver cirrhosis may promote the development of thrombosis, specifically portal vein thrombosis (PVT), which is considered an obstacle in orthotopic liver transplantation (OLT).
The ADAMTS-13 protein is an enzyme, Willebrand factor-cleaving protease (VWFCP). In vascular injury, von Willebrand factor (VWF) together with platelets initiates the formation of thrombus. It also serves as a carrier for factor VIII in plasma. Its deficiency is responsible for von Willebrand’s disease and can lead to oncogenesis.
Portal vein thrombosis (PVT) dramatically changes the prognosis of cirrhotic patients, especially those waiting for liver transplantation. However, the possible contribution to PVT of von Willebrand factor (VWF) and ADAMTS-13 is poorly documented.
So, this study aimed to evaluate the relation of serum level of ADAMTS -13 and portal vein thrombosis in patients with liver cirrhosis.
To elucidate our results, this was a cross sectional, analytical study carried out on 84 subjects, this study was conducted on HCV patients with and without portal vein thrombosis and a healthy population who was considered as the control group. Subjects in our study were recruited from Outpatient Clinic, Internal Medicine, Gastroenterology and Hepatology department, Faculty of Medicine, Menoufia University during the period from March 2020 to August 2020.
All subjects randomly divided into three groups, group I: included 28 cirrhotic patients with portal vein thrombosis, group II: included 28 cirrhotic patients without portal vein thrombosis, and group III: included 28 apparently healthy individual as a control group.